Inventiva H1 2026: Loss Narrows to €69.5M, Cash at €233.9M

Inventiva reported on 28 September 2026 a first-half net loss of €69.5 million, narrower than the €175.9 million loss for the same period a year earlier, with cash and cash equivalents of €166.1 million plus €67.8 million in short-term deposits as of 30 June 2026. The French clinical-stage biopharmaceutical company, listed on Euronext Paris and Nasdaq under the ticker IVA, said it expects topline results from its Phase 3 NATiV3 trial of lanifibranor in the fourth quarter of 2026 and reaffirmed the cash runway guidance it issued on 30 July 2026.

Context — why Inventiva's cash position matters now

Inventiva's first half was defined by a financing overhaul rather than revenue. The company recorded no revenues in the first six months of 2026, down from €4.5 million a year earlier, when revenue came from the 2022 license agreement with Chia Tai Tianging Pharmaceutical Group that was later assigned to Chia Tai Tianging (Guangzhou) Co., Ltd.

The absence of revenue puts the entire burden on the balance sheet, which is why the June 2026 refinancing dominates the period. Inventiva pulled in €103.0 million gross from an offering of 27,272,727 American Depositary Shares and €75.0 million gross from Tranches A and B of a debt financing with funds and accounts managed by BlackRock and Claret Capital Partners.

Those inflows were partly consumed by the repayment of existing European Investment Bank loans totaling €62.2 million and the repurchase of EIB warrants for an aggregate €50.0 million. The net effect was €47.7 million of cash generated from financing activities, versus €104.8 million in the first half of 2025, which reflected the 2024 Structured Financing.

Operating burn also improved. Net cash used in operating activities fell to €45.4 million from €53.7 million, which the company attributed to a favorable working capital change partly offset by higher spending on the NATiV3 Phase 3 trial and pre-commercial preparation.

What triggered the update now is the trial calendar: the last patient completed the final 72-week visit in NATiV3 on 2 September 2026, putting topline readout within sight. Macro conditions are not addressed in the report, and the company gives no market backdrop.

Data — what the numbers show

Research and development expenses reached €46.2 million in the first half of 2026, up 3.0% from €44.9 million a year earlier, driven by lanifibranor's clinical development and carrying no preclinical research costs after those activities were discontinued in mid-2025.

Marketing and business development expenses rose to €2.6 million from €0.7 million, and general and administrative expenses climbed to €22.2 million from €14.7 million, a €7.5 million increase that included €4.7 million of higher personnel costs, share-based compensation, consulting fees and expenses tied to potential commercial development of lanifibranor if approved.

Metric (€ thousands)	H1 2026	H1 2025
Revenues	20	4,454
Net operating loss	(70,388)	(62,940)
Net financial income (loss)	907	(113,224)
Net loss	(69,467)	(175,882)
Basic/diluted loss per share (€)	(0.25)	(1.62)

The net financial result swung to positive €0.9 million from a loss of €113.2 million, mainly because the prior year carried fair-value charges on warrants and convertible instruments. The 2026 figure still absorbed a €16.2 million non-cash IFRS fair-value impact from instruments tied to the EIB restructuring, the Lenders' Warrants and the embedded convertible option in the first €35.0 million tranche of the debt financing.

That was offset by €4.8 million of income from cash equivalents and net foreign exchange gains, against €20.0 million of interest and related financial expenses, including €11.2 million from the EIB loan repayment and €7.4 million of interest on royalty certificates issued in 2023 and 2024. Weighted average shares outstanding rose to 273,582,870 from 108,839,636, which explains why the per-share loss fell faster than the net loss.

Analysis — what it means for markets and sectors

Inventiva now sits in the small cohort of clinical-stage MASH developers carrying a fully enrolled Phase 3 asset with a near-term readout. The company says lanifibranor is the only pan-PPAR agonist in clinical development for MASH, targeting all three PPAR isoforms, a profile it argues supports the tolerability observed to date. The U.S. FDA has granted Breakthrough Therapy and Fast Track designations.

The second-order exposure runs through the metabolic and liver-disease complex. A favorable NATiV3 readout would put Inventiva on a path the company says leads to regulatory submission in the first half of 2027 and a potential U.S. launch of lanifibranor in 2028, subject to FDA approval. Any competing oral MASH therapy now faces a validation question, and contract manufacturers, specialty pharmacies and hepatology-focused diagnostics stand as downstream beneficiaries if the market expands.

The counter-argument is financial, not scientific. Inventiva states plainly that at the date of the release its current cash and cash equivalents are not sufficient to cover operating needs as currently planned for the next twelve months. The runway to the end of the second quarter of 2027 assumes the completed equity offering, the EIB transactions and the issuance of Tranches A and B of the debt financing.

Extending that to the start of the first quarter of 2028 requires Tranche C of the debt financing to be issued for up to €55.0 million gross and the Tranche 3 warrants issued in the Structured Financing to be exercised in full for up to €116.0 million. Both are contingent, and the company excluded any potential milestones payable to or by it, and any spending on additional product candidates, from those estimates.

Positioning is therefore event-driven. Holders of IVA are effectively long a binary clinical catalyst with a funding overhang attached, and the dilution already delivered this year — the weighted share count nearly tripled — means existing holders have paid for the readout in advance. The company did not disclose pricing terms or demand details for the June offering.

Outlook — what to watch next

Three dated catalysts frame the next two quarters. Topline NATiV3 results are expected in the fourth quarter of 2026, and the company will present at the American Association for the Study of Liver Diseases meeting in Denver on 5-9 November 2026. Third-quarter revenues and cash and cash equivalents are due on 23 November 2026, before European and U.S. market open.

Beyond the calendar, the gate is financing. Issuance of Tranche C and full exercise of the Tranche 3 warrants are the conditions the company itself attaches to reaching the start of the first quarter of 2028, so any disclosure on either moves the runway arithmetic rather than the science.

The report names no price levels, moving averages or yield thresholds for the shares, and this article supplies none. Management hosts a webcast at 8:00 AM New York time today, 2:00 PM Paris time, to discuss the half-year results, with a replay to follow on the company's website.

Frequently Asked Questions

What does Inventiva's cash runway mean for retail investors?

Inventiva says its existing cash, deposits and completed financings fund operations as currently planned only until the end of the second quarter of 2027. The company explicitly states that current cash is not sufficient for the next twelve months. Reaching the start of the first quarter of 2028 depends on Tranche C of the debt financing and full exercise of the Tranche 3 warrants, neither of which has occurred.